Stereotactic Radiotherapy and Image-guided Intensity Modulated Radiotherapy for Spinal Metastatic Tumors

Summary

Data of 100 patients with spinal metastatic tumor who received stereotactic radiotherapy or conventionally-fractionated image-guided intensity-modulated radiotherapy in the multi-center of the research group from July 2019 to June 2021 will be collected, as well as their follow-up data.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.

Conditions

• Radiotherapy
• Spine Metastases
• Radiosurgery

Interventions

RADIATION

Stereotactic radiotherapy

Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).

RADIATION

Conventionally-fractionated image- guided Intensity modulated radiotherapy

Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.

Sponsors & Collaborators

• Mianyang Central Hospital

  collaborator OTHER

• Second Hospital of Shanxi Medical University

  collaborator OTHER

• Qingdao chengyang hospital

  collaborator UNKNOWN

• Qingdao Hiser Medical Group

  collaborator OTHER

• Beijing 302 Hospital

  collaborator OTHER

• Guangxi Ruikang Hospital

  collaborator OTHER

• Third Affiliated Hospital of Guizhou Medical University

  collaborator UNKNOWN

• Panjin Liaohe Oilfield Gem Flower Hospital

  collaborator OTHER

• Tang-Du Hospital

  collaborator OTHER

• Peking University Third Hospital

  lead OTHER

Principal Investigators

• Junjie Wang, MD · Peking University Third Hospital

• Fei Xu, M Med · Peking University Third Hospital

• Hongqing Zhuang, M Med · Peking University Third Hospital

• Xiaobo Du, MD · Mianyang Central Hospital

• Jie Li, M Med · Mianyang Central Hospital

• Xiang Song, M Med · Second Hospital of Shanxi Medical University

• Lei Zhang, M Med · Second Hospital of Shanxi Medical University

• Jianguo Zhang, M Med · Qingdao chengyang people's hospital

• Peng Liu, M Med · Qingdao Hiser Medical Group

• Xuezhang Duan, MD · Beijing 302 Hospital

• Zuping Lian, MD · Guangxi Ruikang Hospital

• Liang Liu, MD · Third Affiliated Hospital of Guizhou Medical University

• Longhai Shen, M Med · Panjin Liaohe Oilfield Gem Flower Hospital

• Dongjie He, M Med · Tang-Du Hospital

• Xuemin Li, MD · Peking University Third Hospital

• Yi Chen, MD · Peking University Third Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-06-10

Primary Completion

2021-05-31

Completion

2022-05-31

Countries

• China

Study Locations